top of page

Forward Looking Statement


This website, its content and various remarks we make contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Neurocentria’s plans, strategies and expectations for its preclinical and clinical advancement of its drug development programs, including its ongoing clinical trials of and planned clinical trial of L-TAMS, NRCT-101, NRCT-101SR and NRCT-101SR-c, Magtein or any other compound, material or product; its expectations regarding regulatory interactions; the potential benefits of Neurocentria’s product candidates; its key milestones for 2022; and its plans regarding future data presentations. Statements made in this presentation, including statements about Neurocentria’s beliefs, plans and expectations, are forward-looking statements. The words "anticipate," "expect," "hope," "plan," "potential," "possible," "will," "believe," "estimate," "intend," "may," "predict," "project," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Neurocentria may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of known and unknown risks, uncertainties and other important factors, including: Neurocentria’s ability to obtain additional funding and to continue as a going concern; the impact of the COVID-19 pandemic; the ability to successfully demonstrate the efficacy and safety of Neurocentria’s product candidates and future product candidates; the preclinical and clinical results for Neurocentria’s product candidates, which may not support further development and marketing approval; the potential advantages of Neurocentria’s product candidates; the content and timing of decisions made by the FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, which may affect the initiation, timing and progress of preclinical studies and clinical trials of Neurocentria’s product candidates; Neurocentria’s ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Neurocentria’s ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; and general economic and market conditions. Forward-looking statements represent management's current expectations and are inherently uncertain. Except as required by law, Neurocentria does not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

bottom of page